QURE — uniQure N.V.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1590560 · Netherlands
Last close
$20.78
Market Cap
$1.46B
52W High
$51.72
52W Low
$8.73
ADV30
1,912,946
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 5,196,000 4,960,000 -53,402,000 -61,217,000 940,551,000 98,442,000 645,898,000
Jun 2026 5,841,000 5,491,000 -44,676,000 -81,059,000 985,103,000 413,027,000 661,053,000
Mar 2026 3,562,000 3,343,000 -44,269,000 -53,535,000 778,706,000 139,994,000 629,363,000
Dec 2025 5,568,000 5,133,000 -51,494,000 -37,086,000 824,908,000 80,240,000 626,007,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-192,215,000
Investing CF
$-558,282,000
Financing CF
$253,672,000
CapEx
$-742,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.33
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,524,747,000
Inventory
—
Receivables
$4,804,000
ST Investments
$570,021,000
EBIT TTM
$-176,262,000
Pretax Income TTM
$-233,808,000
Interest Exp TTM
$57,546,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$20,167,000
EBITDA
$-184,168,000
Free Cash Flow
$-167,192,128
Enterprise Value
$1,413,188,224
Total Cash
$668,462,976
Total Debt
$559,638,016
Shares Out
70,138,860
Trailing EPS
$-3.51
Book Value
$4.21
ROE
-89.0%
ROA
-13.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 16,098,000 -187,827,000 -198,971,000 824,908,000 626,007,000 198,901,000 -177,963,000
Dec 2024 27,119,000 -182,180,000 -239,556,000 556,536,000 563,288,000 -6,752,000 -182,728,000
Dec 2023 15,843,000 -282,486,000 -308,478,000 831,689,000 624,019,000 207,670,000 -145,929,000
Dec 2022 106,483,000 -144,246,000 -126,789,000 704,964,000 228,955,000 476,009,000 -145,060,000

TTM Snapshot

Revenues TTM
$18,672,000
NetIncome TTM
$-252,209,000
OpCashFlow TTM
—
Assets (Latest)
$985,103,000
Forward EPS
$-3.20

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $22.00 · spot: $20.30 · call volume: 3,172 · put volume: 1,386
Expected Move to 2026-12-18: ±$5.30 (26.11%) — implied range $15.00 – $25.60 · ATM straddle on $20.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PCRX Pacira BioSciences, Inc. $1.46B $36.48 —
URGN UroGen Pharma Ltd. $1.47B $29.87 —
KRSA Korsana Biosciences, Inc. $1.48B $32.50 —
RAPP Rapport Therapeutics, Inc. $1.41B $23.76 —
DMRA Damora Therapeutics, Inc. $1.40B $22.56 —

News headlines (Yahoo Finance, 1h cache)

uniQure CEO Defends Huntington’s Therapy Data, Sees Opportunity Ahead of FDA Decision
2026-11-13 23:12 · Yahoo
QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?
2026-11-13 17:16 · Yahoo
uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod
2026-11-13 12:14 · Yahoo
Is uniQure (QURE) Priced Beyond Its Book Value Support?
2026-11-13 03:20 · Yahoo
Reduced Loss And Higher Revenue Could Shift The Case For uniQure Stock
2026-11-06 02:16 · Yahoo
uniQure N.V. Q3 2026 Earnings Call Summary
2026-11-04 22:55 · Yahoo
uniQure (QURE) Q3 2026 Earnings Call Transcript
2026-11-04 19:45 · Yahoo
uniQure Q3 Earnings Call Highlights
2026-11-04 19:14 · Yahoo
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates
2026-11-04 12:55 · Yahoo
UniQure: Q3 Earnings Snapshot
2026-11-04 12:25 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.